Quick summary
Enfuvirtide (Fuzeon) is the first FDA-approved HIV fusion inhibitor, a 36-amino acid peptide that blocks viral entry into CD4+ T cells by preventing gp41-mediated membrane fusion. Approved in 2003, it is reserved for treatment-experienced patients with multidrug-resistant HIV-1.
Overview
Enfuvirtide (Fuzeon) is an FDA-approved 36 amino acid synthetic peptide that was the first HIV fusion inhibitor and the first of an entirely new class of antiretroviral drugs. Approved in 2003, it is used as part of combination antiretroviral therapy for treatment-experienced adults and pediatric patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy.
Mechanism of action
Enfuvirtide is a biomimetic peptide derived from the C-terminal heptad repeat (HR2) region of HIV-1 gp41. During viral entry, gp41 undergoes a conformational rearrangement in which its HR1 and HR2 domains fold together to form a six-helix bundle, driving fusion of the viral and host cell membranes. Enfuvirtide binds to the HR1 domain of gp41 in a sequence-specific manner, sterically blocking the HR2 domain from interacting with HR1. By preventing six-helix bundle formation, enfuvirtide arrests the fusion process before viral RNA can be delivered into the CD4+ T lymphocyte, effectively halting infection at the cell entry step. This pre-fusion mechanism is entirely distinct from all other antiretroviral drug classes, preserving activity against strains resistant to reverse transcriptase or protease inhibitors.
Dosing protocols
| Purpose | Route | Dosage | Frequency | Notes |
|---|---|---|---|---|
| HIV-1 treatment in treatment-experienced adults | subcutaneous | 90–90 mg | twice daily | 90 mg (1 mL) injected subcutaneously into the upper arm, anterior thigh, or abdomen twice daily. Rotate injection sites. Reconstitute lyophilized powder in sterile water before use. |
Dosing information is for educational purposes only. Consult a qualified healthcare professional before using any peptide.
Research summary
The pivotal TORO-1 and TORO-2 Phase III trials (2,000+ treatment-experienced patients) demonstrated that enfuvirtide added to an optimized background regimen reduced HIV-1 RNA by an additional 1.0 log10 copies/mL compared to background regimen alone at 24 weeks. FDA approval was granted in 2003. Resistance emerges via mutations in the HR1 region of gp41. Its use is now largely reserved for heavily treatment-experienced patients with multidrug-resistant HIV, given that newer oral agents have simplified regimens considerably.[1][2][3][4][5]
Evidence grading
Each claimed benefit is graded by the strength of available evidence. Grades reflect study quality, not effect size.
Strong = multiple RCTs · Moderate = limited trials or observational · Preliminary = animal or in vitro only · Insufficient = anecdotal or no published data
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with Enfuvirtide for synergistic effects.
Legal status
FDA-approved since March 2003 for HIV-1 infection in treatment-experienced patients. Administered as subcutaneous injection twice daily; requires patient training for self-injection. Not a controlled substance. Requires co-administration with other antiretroviral agents.
Sourcing & access
Prescription required
Enfuvirtide is an FDA-approved prescription medication available through licensed healthcare providers, telehealth platforms, and 503A/503B compounding pharmacies.
Frequently asked questions
Enfuvirtide (brand name Fuzeon) is a 36-amino acid synthetic peptide and the first FDA-approved HIV fusion inhibitor, approved in 2003. It is used in treatment-experienced patients with drug-resistant HIV-1 who have failed multiple prior antiretroviral regimens. As a peptide drug, it represents a distinct mechanistic class from nucleoside analogues and protease inhibitors.
Enfuvirtide binds the HR1 (heptad repeat 1) domain of the HIV-1 gp41 transmembrane protein, preventing the conformational change required to form the six-helix bundle that drives viral-host membrane fusion. By interrupting this pre-entry fusion step, enfuvirtide blocks viral entry into CD4-positive T cells before HIV RNA reaches the cytoplasm, offering a mechanism entirely distinct from post-entry antiretrovirals.
Use has declined substantially because enfuvirtide requires twice-daily subcutaneous injections, and injection site reactions (ISRs) occur in virtually all patients. Most patients develop painful nodules, redness, and induration at injection sites. Additionally, newer oral antiretrovirals with simpler dosing schedules, fewer side effects, and equivalent or superior efficacy have replaced enfuvirtide in most salvage therapy regimens.
Nearly universal injection site reactions (ISR) — including pain, nodules, redness, and induration — are the defining tolerability issue. Clinically significant side effects include an increased rate of bacterial pneumonia compared to background HIV populations, peripheral neuropathy, insomnia, fatigue, and rare hypersensitivity reactions. Hypersensitivity can recur and may be systemic upon rechallenge, requiring permanent discontinuation.
Research references
- Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America (TORO 1 Trial)PubMed
- Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia (TORO 2 Trial)PubMed
- Enfuvirtide, a New Fusion Inhibitor for Therapy of Human Immunodeficiency Virus InfectionPubMed
- Enfuvirtide (T-20): A Novel Human Immunodeficiency Virus Type 1 Fusion InhibitorPubMed
- Durable Efficacy of Enfuvirtide over 48 Weeks in Heavily Treatment-Experienced HIV-1-Infected Patients in TORO 1 and 2PubMed